Literature DB >> 7492444

HIV glycoprotein 41 and complement factor H interact with each other and share functional as well as antigenic homology.

C Pintér1, A G Siccardi, L Lopalco, R Longhi, A Clivio.   

Abstract

We have shown that complement factor H (CFH) interacts with HIV-1 at the level of the sequence Env 105-119, contained in the C1 domain of gp120. CFH interaction with HIV was evident only after dissociation of the Env complex induced by exposure to sCD4. We hypothesized that CFH could act as a gp41 analog in the interaction with Env 105-119. A panel of partially overlapping, synthetic peptides reproducing the extracellular portion of gp41 was therefore used to compete the binding of CFH to Env 105-119. Three sets of peptides that competed this interaction were identified. These peptides defined a region of functional homology between the gp41 molecule and CFH (Env 580-600), and two regions of interaction (Env 620-640 and Env 650-670). In addition to this, a monoclonal antibody directed against peptide Env 580-600 and a polyclonal mouse antiserum raised against recombinant gp41 were shown to recognize CFH in Western blots and ELISA, respectively, also defining a region of antigenic homology between gp41 and CFH. These data provide evidence for interaction and molecular mimicry between an HIV structural protein and a negative regulator of the complement pathway. We show here that CFH can interact with both HIV Env proteins, suggesting a possible and efficient mechanism of downregulation of the complement cascade at the surface of infected cells.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7492444     DOI: 10.1089/aid.1995.11.971

Source DB:  PubMed          Journal:  AIDS Res Hum Retroviruses        ISSN: 0889-2229            Impact factor:   2.205


  15 in total

Review 1.  Complement control protein factor H: the good, the bad, and the inadequate.

Authors:  Viviana P Ferreira; Michael K Pangburn; Claudio Cortés
Journal:  Mol Immunol       Date:  2010-08       Impact factor: 4.407

2.  Differential activity of candidate microbicides against early steps of HIV-1 infection upon complement virus opsonization.

Authors:  Mohammad-Ali Jenabian; Héla Saïdi; Charlotte Charpentier; Hicham Bouhlal; Dominique Schols; Jan Balzarini; Thomas W Bell; Guido Vanham; Laurent Bélec
Journal:  AIDS Res Ther       Date:  2010-06-14       Impact factor: 2.250

3.  Integrity of Glycosylation Processing of a Glycan-Depleted Trimeric HIV-1 Immunogen Targeting Key B-Cell Lineages.

Authors:  Anna-Janina Behrens; Abhinav Kumar; Max Medina-Ramirez; Albert Cupo; Kevin Marshall; Victor M Cruz Portillo; David J Harvey; Gabriel Ozorowski; Nicole Zitzmann; Ian A Wilson; Andrew B Ward; Weston B Struwe; John P Moore; Rogier W Sanders; Max Crispin
Journal:  J Proteome Res       Date:  2018-02-08       Impact factor: 4.466

4.  A novel sialic acid binding site on factor H mediates serum resistance of sialylated Neisseria gonorrhoeae.

Authors:  S Ram; A K Sharma; S D Simpson; S Gulati; D P McQuillen; M K Pangburn; P A Rice
Journal:  J Exp Med       Date:  1998-03-02       Impact factor: 14.307

Review 5.  Innate immune evasion strategies by human immunodeficiency virus type 1.

Authors:  Debjani Guha; Velpandi Ayyavoo
Journal:  ISRN AIDS       Date:  2013-08-12

Review 6.  Current Progress of Virus-mimicking Nanocarriers for Drug Delivery.

Authors:  Masaharu Somiya; Qiushi Liu; Shun'ichi Kuroda
Journal:  Nanotheranostics       Date:  2017-10-31

Review 7.  Complement and its role in protection and pathogenesis of flavivirus infections.

Authors:  Panisadee Avirutnan; Erin Mehlhop; Michael S Diamond
Journal:  Vaccine       Date:  2008-12-30       Impact factor: 3.641

8.  Binding of complement factor H to loop 5 of porin protein 1A: a molecular mechanism of serum resistance of nonsialylated Neisseria gonorrhoeae.

Authors:  S Ram; D P McQuillen; S Gulati; C Elkins; M K Pangburn; P A Rice
Journal:  J Exp Med       Date:  1998-08-17       Impact factor: 14.307

9.  Efficient destruction of human immunodeficiency virus in human serum by inhibiting the protective action of complement factor H and decay accelerating factor (DAF, CD55).

Authors:  H Stoiber; C Pintér; A G Siccardi; A Clivio; M P Dierich
Journal:  J Exp Med       Date:  1996-01-01       Impact factor: 14.307

10.  Human Immunodeficiency Virus Proteins Mimic Human T Cell Receptors Inducing Cross-Reactive Antibodies.

Authors:  Robert Root-Bernstein
Journal:  Int J Mol Sci       Date:  2017-10-03       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.